Randomised clinical trial: Certolizumab pegol for fistulas in Crohn's disease - Subgroup results from a placebo-controlled study

Alimentary Pharmacology and Therapeutics

Volumn 33, Issue 2, 2011, Pages 185-193

  Schreiber, S ^a   Lawrance, I C ^b   Thomsen, O O ^c   Hanauer, S B ^d   Bloomfield, R ^e   Sandborn, W J ^f  

^a UNIVERSITY OF KIEL   (Germany)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^e UCB PHARMA   (Belgium)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CERTOLIZUMAB PEGOL; PLACEBO;

ABSCESS; ADULT; ANUS FISTULA; ARTHRALGIA; ARTICLE; BUTTOCK FISTULA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROHN DISEASE; CROHN DISEASE ACTIVITY INDEX; DIGESTIVE SYSTEM FISTULA; DISEASE ACTIVITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HUMAN; INFECTION; INGUINAL FISTULA; INJECTION SITE PAIN; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; OUTCOME ASSESSMENT; PERINEUM ABSCESS; PERINEUM FISTULA; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM;

ADULT; CROHN DISEASE; DIGESTIVE SYSTEM FISTULA; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; REGRESSION ANALYSIS; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 78650275013     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2010.04509.x     Document Type: Article

References (26)

1. Felley C, Mottet C, Juillerat P, et al. Fistulizing Crohn's disease. Digestion 2007; 76: 109-12.
2. Schwartz DA, Loftus EV Jr, Tremaine WJ, et al. The natural history of fistulizing Crohn's disease in Olmsted County, Minnesota. Gastroenterology 2002; 122: 875-80.
3. Kamm MA, Ng SC,. Perianal fistulizing Crohn's disease: a call to action. Clin Gastroenterol Hepatol 2008; 6: 7-10.
4. Nielsen OH, Rogler G, Hahnloser D, Thomsen OO,. Diagnosis and management of fistulizing Crohn's disease. Nat Clin Pract Gastroenterol Hepatol 2009; 6: 92-106.
5. Judge TA, Lichtenstein GR,. Treatment of fistulizing Crohn's disease. Gastroenterol Clin North Am 2004; 33: 421-54.
6. Sandborn WJ, Fazio VW, Feagan BG, Hanauer SB,. AGA technical review on perianal Crohn's disease. Gastroenterology 2003; 125: 1508-30.
7. Thia KT, Mahadevan U, Feagan BG, et al. Ciprofloxacin or metronidazole for the treatment of perianal fistulas in patients with Crohn's disease: a randomized, double-blind, placebo-controlled pilot study. Inflamm Bowel Dis 2009; 15: 17-24.
8. Brandt LJ, Bernstein LH, Boley SJ, Frank MS,. Metronidazole therapy for perineal Crohn's disease: a follow-up study. Gastroenterology 1982; 83: 383-7.
9. Pearson DC, May GR, Fick GH, Sutherland LR,. Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis. Ann Intern Med 1995; 123: 132-42.
10. Peyrin-Biroulet L, Deltenre P, De Suray N, Branche J, Sandborn WJ, Colombel JF,. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol 2008; 6: 644-53.
11. Colombel JF, Schwartz DA, Sandborn WJ, et al. Adalimumab for the treatment of fistulas in patients with Crohn's disease. Gut 2009; 58: 940-8.
12. Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999; 340: 1398-405. (Pubitemid 29205403)
13. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004; 350: 876-85.
14. Schreiber S, Khaliq-Kareemi M, Lawrance IC, et al. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med 2007; 357: 239-50. (Pubitemid 47080388)
15. Best WR, Becktel JM, Singleton JW, Kern F Jr,. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology 1976; 70: 439-44.
16. Irvine EJ, Feagan B, Rochon J, et al. Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn's Relapse Prevention Trial Study Group. Gastroenterology 1994; 106: 287-96.
17. Irvine EJ,. Development and subsequent refinement of the inflammatory bowel disease questionnaire: a quality-of-life instrument for adult patients with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 1999; 28: S23-7.
18. Breuer-Katschinski BD, Hollander N, Goebell H,. Effect of cigarette smoking on the course of Crohn's disease. Eur J Gastroenterol Hepatol 1996; 8: 225-8.
19. Cosnes J, Carbonnel F, Carrat F, Beaugerie L, Cattan S, Gendre J,. Effects of current and former cigarette smoking on the clinical course of Crohn's disease. Aliment Pharmacol Ther 1999; 13: 1403-11.
20. Lindberg E, Jarnerot G, Huitfeldt B,. Smoking in Crohn's disease: effect on localisation and clinical course. Gut 1992; 33: 779-82.
21. Lautenbach E, Berlin JA, Lichtenstein GR,. Risk factors for early postoperative recurrence of Crohn's disease. Gastroenterology 1998; 115: 259-67.
22. Martin G, Heyen F, Dube S,. Factors of recurrence in Crohn disease. Ann Chir 1994; 48: 685-90.
23. Van Der HF, Dijkstra A, Weersma RK, et al. Effects of active and passive smoking on disease course of Crohn's disease and ulcerative colitis. Inflamm Bowel Dis 2009; 15: 1199-207.
24. D'Haens G, Baert F, Van Assche G, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 2008; 371: 660-7.
25. Fefferman DS, Lodhavia PJ, Alsahli M, et al. Smoking and immunomodulators do not influence the response or duration of response to infliximab in Crohn's disease. Inflamm Bowel Dis 2004; 10: 346-51.
26. Vermeire S, Louis E, Carbonez A, et al. Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn's disease. Am J Gastroenterol 2002; 97: 2357-63.